Briggs Morrison
CIK 1654430 · President, Head of R&D · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.59M
Companies
8
Total Filings
64
Lifetime Open-Market Net
-$27.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARVN | Director | 111,548 | $8.18 | $912.5K | -$2.18M | 14 | 2026-06-26 |
| CRSP | Director | — | $47.55 | — | $0 | 2 | 2026-06-09 |
| HOWL | Director | — | $0.47 | — | $0 | 5 | 2025-06-13 |
| Carisma Therapeutics Inc. (CARM) Delisted | Director | — | $0.00 | — | $0 | 2 | 2024-06-27 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 4,800 | $2.65 | $12.7K | $96.0K | 5 | 2024-06-20 |
| SNDX | Director | 34,836 | $19.31 | $672.7K | -$25.70M | 27 | 2024-02-09 |
| Codiak BioSciences, Inc. (CDAK) Delisted | Director | 4,761 | $0.06 | $271 | $100.0K | 2 | 2021-02-17 |
| NXTC | Director | — | $5.14 | — | $0 | 2 | 2020-06-15 |
Recent Filings · Page 2 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-24 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2024-02-09 | SNDX | Grant (A) | +17,000 | $0 | EDGAR |
| 2023-08-10 | SNDX | Mixed | — | -$501.9K | EDGAR |
| 2023-08-09 | SNDX | Notice (144) | −52,855 | -$964.6K | EDGAR |
| 2023-07-11 | SNDX | Mixed | — | -$614.5K | EDGAR |
| 2023-07-10 | SNDX | Notice (144) | −52,855 | -$1.07M | EDGAR |
| 2023-06-23 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | ARVN | Grant (A) | +4,121 | $0 | EDGAR |
| 2023-06-12 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | SNDX | Notice (144) | −52,855 | -$1.13M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.